trastuzumab deruxtecan
Trastuzumab Deruxtecan Beats Standard Even in Very Low HER2 Metastatic Breast Cancer
Already approved for HER2-low metastatic breast cancer (MBC) after at least one line of chemotherapy, the ...
AUGUST 7, 2024
Trastuzumab Deruxtecan Demonstrates Benefit Across an Array of HER2-Expressing Tumors
The antibody–drug conjugate trastuzumab deruxtecan (T-DXd) (Enhertu, Daiichi Sankyo/AstraZeneca) is emerging ...
JULY 7, 2023
Patients With HER2-Low Early Breast Cancer Respond to Trastuzumab Deruxtecan
Neoadjuvant trastuzumab deruxtecan (T-DXd) (Enhertu, Daiichi Sankyo) produced responses and decreased HER2 ...
DECEMBER 28, 2022
Phase 3 Trial for Metastatic Breast Cancer Is Practice-Changing on Multiple Levels
Based on results from a new phase 3 trial, clinicians should now stratify patients with metastatic breast cancer ...
JUNE 21, 2022
Breast Cancer Drug Showing High Rates of Activity in HER2+ Lung and Gastric Cancers
A new-generation antibody drug conjugate approved for the treatment of HER2-positive breast cancer demonstrated ...
JANUARY 4, 2022
